{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["033b1305-e8d0-4e5a-bc49-91f94f2762a3", "Q2", 319778, "COVIDIEN LP", 186509, "COVIDIEN LP", 2012, "second_quarter", "2012-07-18T12:50:30.033000-04:00", 440000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/033b1305-e8d0-4e5a-bc49-91f94f2762a3/\", \"filing_uuid\": \"033b1305-e8d0-4e5a-bc49-91f94f2762a3\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2012, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/033b1305-e8d0-4e5a-bc49-91f94f2762a3/print/\", \"filing_document_content_type\": \"text/html\", \"income\": null, \"expenses\": \"440000.00\", \"expenses_method\": \"a\", \"expenses_method_display\": \"Method A - Reporting amounts using LDA definitions only\", \"posted_by_name\": \"Timothy J. McBride VP Global Government Affairs\", \"dt_posted\": \"2012-07-18T12:50:30.033000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": \"United States of America\", \"registrant_address_1\": \"900 7th Street, NW\", \"registrant_address_2\": \"Suite 975\", \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20001\", \"registrant\": {\"id\": 319778, \"url\": \"https://lda.senate.gov/api/v1/registrants/319778/\", \"house_registrant_id\": 39509, \"name\": \"COVIDIEN LP\", \"description\": \"Medical Products Manufacturer\", \"address_1\": \"701 8th Street\", \"address_2\": \"Suite 620\", \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20001\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"WHITNEY GARDINER\", \"contact_telephone\": \"+1 202-442-3647\", \"dt_updated\": \"2022-04-06T16:08:25.664832-04:00\"}, \"client\": {\"id\": 186509, \"url\": \"https://lda.senate.gov/api/v1/clients/186509/\", \"client_id\": 12, \"name\": \"COVIDIEN LP\", \"general_description\": null, \"client_government_entity\": false, \"client_self_select\": true, \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"DC\", \"ppb_state_display\": \"District of Columbia\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2009-06-04\"}, \"lobbying_activities\": [{\"general_issue_code\": \"CPT\", \"general_issue_code_display\": \"Copyright/Patent/Trademark\", \"description\": \"S.23/H.R.1249: America Invents Act (all provisions).\", \"foreign_entity_issues\": \"As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 35735, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"WHITNEY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"GARDINER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 41831, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JOHN\", \"nickname\": null, \"middle_name\": \"CHRISTOPHER\", \"last_name\": \"KALAVRITINOS\", \"suffix\": \"jr\", \"suffix_display\": \"JR\"}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 51224, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"TIMOTHY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"MCBRIDE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"Issues involving controlled substance and pain and addiction drugs generally;  H.R. 2119: Ryan Creedon Act of 2011; Issues related to acetaminophen\", \"foreign_entity_issues\": \"As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 35735, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"WHITNEY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"GARDINER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 41831, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JOHN\", \"nickname\": null, \"middle_name\": \"CHRISTOPHER\", \"last_name\": \"KALAVRITINOS\", \"suffix\": \"jr\", \"suffix_display\": \"JR\"}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 51224, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"TIMOTHY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"MCBRIDE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"TRD\", \"general_issue_code_display\": \"Trade (domestic/foreign)\", \"description\": \"Free Trade Agreement; HR 3078: United State Columbia Trade Promotion Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement); HR 3079: United States Panama Trade Promotion Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement) HR 3080: United States - Korea Free Trade Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement)\", \"foreign_entity_issues\": \"As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 35735, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"WHITNEY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"GARDINER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 51224, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"TIMOTHY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"MCBRIDE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"TAX\", \"general_issue_code_display\": \"Taxation/Internal Revenue Code\", \"description\": \"International tax on foreign direct investment generally; Corporate Tax Reform generally; S.1346: Stop Tax Haven Abuse Act (all provisions); H.R. 62: International Tax Competitiveness Act of 2011 (all provisions).\", \"foreign_entity_issues\": \"As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 35735, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"WHITNEY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"GARDINER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 51224, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"TIMOTHY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"MCBRIDE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"General issues related to FDA device approval process; issues related to Patient Protection and Affordable Care Act Implementation (Accountable Care Organization, Medical Device Tax); S.17/S.262/H.R.436/H.R.488/H.R.734: Medical Device Access and Innovation Protection Act (all provisions); HEU/LEU related issues for Nuclear Medicine. S.99: American Medical Isotopes Production Act (all provisions). H.R. 3209: Premarket Predictability Act (All provisions related to the FDA and the regulation of medical devices generally); \\nH.R. 3203: Novel Device Regulatory Relief Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3230: Keeping America Competitive Through Harmonization Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3205: FDA Renewing Efficiency from Outside Review Management Act. (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3211: Humanitarian Device Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3208: Patients Come First Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3206: Cultivating Scientific Experts to  Foster Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3214: Food and Drug Administration Mission Reform Act (All provisions related to the FDA and the regulation of medical devices generally);\\nH.R. 3204: Guidance Accountability and Transparency Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1700: The Medical Device Regulatory Improvement Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1865: The Patient Access to Medical Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1943: Novel Device Regulatory Relief Act of 2011(All provisions related to the FDA and the regulation of medical devices generally); S. 1972: A bill to amend the Food and Drug Administrations mission (All provisions related to the FDA and the regulation of medical devices generally); S. 1995: A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes (All provisions related to the FDA and the regulation of medical devices generally); S.3187: Food and Drug Administration Safety and Innovation Act as well as Amendment 2151 on reclassification of hydrocodone sponsored by Senator Manchin; Coverage issues for  Transcutaneous Electronic Stimulation for chronic lower back pain.\", \"foreign_entity_issues\": \"As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 35735, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"WHITNEY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"GARDINER\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 41831, \"prefix\": \"mr\", \"prefix_display\": \"MR.\", \"first_name\": \"JOHN\", \"nickname\": null, \"middle_name\": \"CHRISTOPHER\", \"last_name\": \"KALAVRITINOS\", \"suffix\": \"jr\", \"suffix_display\": \"JR\"}, \"covered_position\": null, \"new\": false}, {\"lobbyist\": {\"id\": 51224, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"TIMOTHY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"MCBRIDE\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 135, \"name\": \"Food & Drug Administration (FDA)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["033b1305-e8d0-4e5a-bc49-91f94f2762a3"], "units": {}, "query_ms": 172.8880419395864, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}